Cocquyt V - Search Results

1

Stable metabolic disease on FDG-PET provides information on response to endocrine therapy for breast cancer.

Kruse V, VAN DE Wiele C, Maes A, Borms M, Pottel H, VAN Belle S, Cocquyt V. Kruse V, et al. Among authors: cocquyt v. Q J Nucl Med Mol Imaging. 2017 Mar;61(1):108-114. doi: 10.23736/S1824-4785.16.02727-8. Epub 2014 Oct 7. Q J Nucl Med Mol Imaging. 2017. PMID: 25289633

2

Serum tumor markers and PET/CT imaging for tumor recurrence detection.

Kruse V, Cocquyt V, Borms M, Maes A, Van de Wiele C. Kruse V, et al. Among authors: cocquyt v. Ann Nucl Med. 2013 Feb;27(2):97-104. doi: 10.1007/s12149-012-0664-6. Epub 2012 Dec 4. Ann Nucl Med. 2013. PMID: 23420146 Review.

3

Reproducibility of FDG PET based metabolic tumor volume measurements and of their FDG distribution within.

Kruse V, Mees G, Maes A, D'Asseler Y, Borms M, Cocquyt V, Van De Wiele C. Kruse V, et al. Among authors: cocquyt v. Q J Nucl Med Mol Imaging. 2015 Dec;59(4):462-8. Epub 2014 Apr 3. Q J Nucl Med Mol Imaging. 2015. PMID: 24695005

4

CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.

Kruse V, Van de Wiele C, Borms M, Maes A, Pottel H, Sathekge M, Cocquyt V. Kruse V, et al. Among authors: cocquyt v. Nuklearmedizin. 2014 Aug 6;53(4):131-8. doi: 10.3413/Nukmed-0634-13-12. Nuklearmedizin. 2014. PMID: 25100557

5

Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy.

Van Belle SJ, Cocquyt V. Van Belle SJ, et al. Among authors: cocquyt v. Crit Rev Oncol Hematol. 2003 Jul;47(1):1-11. doi: 10.1016/s1040-8428(03)00093-3. Crit Rev Oncol Hematol. 2003. PMID: 12853095 Review.

6

Lobular carcinoma in situ and invasive lobular cancer of the breast.

Cocquyt V, Van Belle S. Cocquyt V, et al. Curr Opin Obstet Gynecol. 2005 Feb;17(1):55-60. doi: 10.1097/00001703-200502000-00010. Curr Opin Obstet Gynecol. 2005. PMID: 15711412 Review.

7

The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?

Kruse V, Denys H, Van Den Broecke R, Van Belle S, Cocquyt V. Kruse V, et al. Among authors: cocquyt v. Springerplus. 2013 May 1;2(1):202. doi: 10.1186/2193-1801-2-202. Print 2013 Dec. Springerplus. 2013. PMID: 23710429 Free PMC article.

8

Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.

Marlier J, Cocquyt V, Brochez L, Van Belle S, Kruse V. Marlier J, et al. Among authors: cocquyt v. Endocrine. 2014 Dec;47(3):878-83. doi: 10.1007/s12020-014-0199-9. Epub 2014 Feb 21. Endocrine. 2014. PMID: 24554495

9

Resection of single metachronous liver metastases from breast cancer stage I-II yield excellent overall and disease-free survival. Single center experience and review of the literature.

Vertriest C, Berardi G, Tomassini F, Vanden Broucke R, Depypere H, Cocquyt V, Denys H, Van Belle S, Troisi RI. Vertriest C, et al. Among authors: cocquyt v. Dig Surg. 2015;32(1):52-9. doi: 10.1159/000375132. Epub 2015 Feb 11. Dig Surg. 2015. PMID: 25675843 Review.

10

Iodine-labeled tamoxifen uptake in primary human breast carcinoma.

Van de Wiele C, Cocquyt V, VandenBroecke R, De Vos F, Van Belle S, Dhaene K, Slegers G, Dierckx RA. Van de Wiele C, et al. Among authors: cocquyt v. J Nucl Med. 2001 Dec;42(12):1818-20. J Nucl Med. 2001. PMID: 11752079 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

80 results

Search Page

Filters